Literature DB >> 28392661

Identification of a Novel Mutation of LAMB3 Gene in a Lybian Patient with Hereditary Epidermolysis Bullosa by Whole Exome Sequencing.

Nadia Laroussi1, Olfa Messaoud1, Mariem Chargui1, Chaima Ben Fayala2, Abdelaziz Elahlafi3, Mourad Mokni4, Anu Bashamboo5, Kenneth McElreavey5, Mohamed Samir Boubaker2, Houda Yacoub Youssef1, Sonia Abdelhak1.   

Abstract

Entities:  

Year:  2017        PMID: 28392661      PMCID: PMC5383759          DOI: 10.5021/ad.2017.29.2.243

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


× No keyword cloud information.
Dear Editor: Hereditary epidermolysis bullosa (HEB) constitutes a diverse group of genodermatoses characterized by trauma-induced skin fragility, blisters and erosions. The fragility of the skin and mucous membranes results from abnormalities in the cytoskeleton of the basal keratinocytes or of the basement membrane zone1. Faced to the great heterogeneity of this disease, long and/or numerous exons of HEB genes, it was necessary to use next generation sequencing techniques, as an approach for disease-gene and variant causing identification2. In this study, we carried out whole exome sequencing (WES) analysis in one Libyan patient in order to identify the molecular aetiology of HEB. The patient is the first child of a consanguineous healthy couple without a HEB familial history, originating from Libya. The baby was born without apparent abnormalities. After three days of birth, blisters followed by erosions and ulceration of skin sites prone to friction appeared. The mucous membranes were affected. Nail dystrophy was also observed. This study was conducted according to the declaration of Helsinki and to the ethical standards of the authors Institutional Review Board (Registration number IRB00005445, FWA00010074). After signing an informed consent, blood samples were collected and genomic DNA was isolated. WES was carried out using 5 µg of the genomic DNA sample. Classical investigation of HEB is generally performed by electronic microscopy or/and immunofluorescence followed by mutational screening. However, this approach is expensive and time-consuming mainly in laboratories lacking logistics and human resources. Large genes like COL7A1 and PLEC1 and the presence of pseudogenes for KRT14 represent a major difficulty to perform molecular diagnosis. Direct sequencing of all COL7A1 coding regions might be challenging as they encompass 118 exons, and more than 70 polymerase chain reaction primer pairs are necessary for the amplification of all coding regions3. In addition, the genetic heterogeneity and the important number of “private mutation” make the genetic diagnosis more challenging even in endogamous populations4. WES has led to the identification of a considerable number of pathogenic mutations in monogenic Mendelian disorders, including skin pathologies5. Indeed, in comparison to individual genes such as COL7A1, Sanger sequencing costs are similar to the entire cost of WES3. The library preparation, capture, sequencing, variant detection and annotation were performed by Oxford Gene Technology (OGT), (London, UK). Filtering steps were initiated by excluding reads with a coverage <20 and polymorphisms with a frequency >1%, according to OGT data, and polymorphisms for each gene involved in HEB were extracted (Table 1). Finally, all the variants reported in the Exome Variant Server and Exome Aggregation Consortium databases were excluded. These analyzes allowed the identification of a novel homozygous variant (c.2701+1G>A) occurring at the 18th donor splice site of LAMB3 gene in the affected sibling, and at the heterozygous state in the clinically unaffected parents. The c.2701+1G>A has been confirmed by Sanger sequencing of the corresponding DNA fragment. This variant was not present in 44 ethnically matched unrelated controls (88 chromosomes).
Table 1

Variants identified after the first filter step (coverage of reads >20, MAF <1%)

GenePolymorphismChromosomal positionHomozygous/HeterozygousType of polymorphismLocalisationMAF (%)Prediction
EVSExAcPolyphenSift
COL7A1rs350182033:48602523HomozygousDeletionIntron99.99840UnknownUnknown
rs667374453:48605076HeterozygousDeletionSplice region04.212NMNM
rs2018398813:48605573HeterozygousNon synonymous codingExon00UnknownTolerated
NR3:48621834HeterozygousSubstitutionIntron00.01633-
FERMT1No variant found for this gene
DSPrs28062346:7563983HomozygousSynonymous codingExon99.998599.91UnknownUnknown
DSTNo variant found for this gene
KRT5No variant found for this gene
KRT14No variant found for this gene
PLECNo variant found for this gene
PKP1rs17227591:201288898HomozygousSubstitutionIntron99.87599.62NMNM
COL17A1NR10:105819535HeterozygousSubstitutionIntron00NMNM
ITGA6No variant found for this gene
ITGB4rs3427594017:73723454HomozygousDeletionIntron99.999100NMNM
LAMA3rs11234080018:21293870HeterozygousDeletionIntron77.8241-NMNM
rs115423318:21511089HomozygousNon synonymous codingExon0100BeningnTolerated
LAMC2No variant found for this gene
LAMB3NR1:209795880HomozygousSubstitutionSplice region00NMNM

MAF: minor allele frequency, EVS: Exome Variant Server, ExAc: Exome Aggregation Consortium, NM: not mentioned, NR: not reported.

Splicing abnormalities are common in human diseases. These mutations can result in either complete skipping of one or more exons, retention of an intron or the introduction of a new splice site within an exon or an intron6. The most deleterious single nucleotide substitutions in donor or acceptor splice sites involve the +1/+2 or −1/−2 positions7. For our patient, the G to T transition at +1 bp position downstream exon 18 is predicted to abolish the 18th donor splice site according to Berkeley Drosophila Genome Project (http://www.fruitfly.org/seq_tools/splice.html). Thus, the affected splice site would lead to an aberrant transcript with an in-frame skipping of the last 82 nucleotides of exon 18. This aberrant splicing is predicted to result in a truncated β3 chain of laminin 332 with a loss of 25% (299 carboxyl-terminal amino acids) of the β3 chain due to a frame shift and a premature termination at codon 904. The predicted β3 chain mutant has 873 amino acids that are identical to the normal β3 chain while the last 31 amino acids are different (Fig. 1). The creation of a premature stop codon could result in the degradation of the LAMB3 mRNA by the nonsense-mediated decay mechanism.
Fig. 1

Schematic representation of the predicted consequences of the donor splice-site mutation c.2701+ 1G>A in LAMB3 gene. (A) Schematic representation of LAMB3 gene. Exons are shown as numbered black rectangles. (B) A focus on exon 18 donor site wild type and mutated sequences. (C) Predicted mRNA and consequences on the predicted protein of LAMB3 gene. (D) Nucleotide sequence with the translated predicted β3 chain of laminin 332. WT: wild type, mRNA: messenger RNA, aa: amino acid, bp: base pair.

The severity of the disease depends on the nature, the location and the impact of the mutation at transcriptional and translational levels. Mutations affecting the short arm of β3 chain of laminin 332 have been reported to be responsible of the Herlitz JEB (H-JEB) phenotype8. The H-JEB is characterized by profound skin fragility and mucocutaneous blistering with loss of fluids and proteins, making affected infants susceptible to infections. The long-term consequences include failure to thrive, anaemia, dyspnoea, pneumonia or sepsis, which explain the high mortality observed within the two first years of life9. For these reasons and to avoid having other children with JEB, the family has requested a molecular diagnosis. By identifying the molecular aetiology of the disease, prenatal diagnosis has been planned to give parents the chance of having an unaffected child. In this paper, we report on the molecular study of a Libyan patient with HEB. This is to our knowledge the first study of a Libyan patient. Our previous studies showed that despite mutational heterogeneity of HEB, some mutations are likely founder and closed to specific geographic regions4. Therefore, screening of c.2701+1G>A mutation could assist in determining the molecular aetiology of HEB among eastern Libyan patients. Taken together, our results demonstrate that whole-exome sequencing could be used as a reliable and time-efficient technique for molecular aetiology determination, especially for heterogeneous disorders like HEB, particularly in unexplored areas.
  9 in total

1.  Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes.

Authors:  Aoi Nakano; Sheau-Chiou Chao; Leena Pulkkinen; Dedee Murrell; Leena Bruckner-Tuderman; Ellen Pfendner; Jouni Uitto
Journal:  Hum Genet       Date:  2001-11-13       Impact factor: 4.132

2.  The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences.

Authors:  M Krawczak; J Reiss; D N Cooper
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

3.  Exome sequencing and the genetic basis of complex traits.

Authors:  Adam Kiezun; Kiran Garimella; Ron Do; Nathan O Stitziel; Benjamin M Neale; Paul J McLaren; Namrata Gupta; Pamela Sklar; Patrick F Sullivan; Jennifer L Moran; Christina M Hultman; Paul Lichtenstein; Patrik Magnusson; Thomas Lehner; Yin Yao Shugart; Alkes L Price; Paul I W de Bakker; Shaun M Purcell; Shamil R Sunyaev
Journal:  Nat Genet       Date:  2012-05-29       Impact factor: 38.330

Review 4.  Splicing in action: assessing disease causing sequence changes.

Authors:  D Baralle; M Baralle
Journal:  J Med Genet       Date:  2005-10       Impact factor: 6.318

Review 5.  Epidermal basement membrane: its molecular organization and blistering disorders.

Authors:  Takuji Masunaga
Journal:  Connect Tissue Res       Date:  2006       Impact factor: 3.417

6.  Mutational founder effect in recessive dystrophic epidermolysis bullosa families from Southern Tunisia.

Authors:  Ahlem Sabrine Ben Brick; Nadia Laroussi; Hela Mesrati; Rym Kefi; Mbarka Bchetnia; Khaled Lasram; Nizar Ben Halim; Lilia Romdhane; Houyem Ouragini; Salaheddine Marrakchi; Mohamed Samir Boubaker; Mounira Meddeb Cherif; Daniele Castiglia; Alain Hovnanian; Sonia Abdelhak; Hamida Turki
Journal:  Arch Dermatol Res       Date:  2013-10-30       Impact factor: 3.017

7.  Herlitz junctional epidermolysis bullosa: diagnostic features, mutational profile, incidence and population carrier frequency in the Netherlands.

Authors:  W Y Yuen; H H Lemmink; K K van Dijk-Bos; R J Sinke; M F Jonkman
Journal:  Br J Dermatol       Date:  2011-11-17       Impact factor: 9.302

Review 8.  Genetics and epigenetics of the skin meet deep sequence.

Authors:  Jeffrey B Cheng; Raymond J Cho
Journal:  J Invest Dermatol       Date:  2012-01-12       Impact factor: 8.551

9.  Mutations in UVSSA cause UV-sensitive syndrome and impair RNA polymerase IIo processing in transcription-coupled nucleotide-excision repair.

Authors:  Yuka Nakazawa; Kensaku Sasaki; Norisato Mitsutake; Michiko Matsuse; Mayuko Shimada; Tiziana Nardo; Yoshito Takahashi; Kaname Ohyama; Kosei Ito; Hiroyuki Mishima; Masayo Nomura; Akira Kinoshita; Shinji Ono; Katsuya Takenaka; Ritsuko Masuyama; Takashi Kudo; Hanoch Slor; Atsushi Utani; Satoshi Tateishi; Shunichi Yamashita; Miria Stefanini; Alan R Lehmann; Koh-ichiro Yoshiura; Tomoo Ogi
Journal:  Nat Genet       Date:  2012-05       Impact factor: 38.330

  9 in total
  3 in total

1.  LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.

Authors:  Hong Zhang; Yao-Zhen Pan; May Cheung; Mary Cao; Chao Yu; Ling Chen; Lei Zhan; Zhi-Wei He; Cheng-Yi Sun
Journal:  Cell Death Dis       Date:  2019-03-08       Impact factor: 8.469

2.  Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis.

Authors:  Jingjing Zhang; Yun Li; Hua Liu; Jiahui Zhang; Jie Wang; Jia Xia; Yu Zhang; Xiang Yu; Jinyan Ma; Masha Huang; Jiahui Wang; Liangzhe Wang; Qian Li; Rutao Cui; Wen Yang; Yingjie Xu; Weiwei Feng
Journal:  J Exp Clin Cancer Res       Date:  2022-01-15

3.  The prognostic and clinical significance of IFI44L aberrant downregulation in patients with oral squamous cell carcinoma.

Authors:  Deming Ou; Ying Wu
Journal:  BMC Cancer       Date:  2021-12-13       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.